Latanoprost 0.005% test formulation is as effective as Xalatan® in patients with ocular hypertension and primary open-angle glaucoma

European Journal of Ophthalmology

Volumn 22, Issue 1, 2011, Pages 19-27

  Allaire, Catherine ^a   Dietrich, Alice ^b   Allmeier, Helmut ^c   Grundmane, Iveta ^d   Mazurpiotrowska, Grazyna ^e   Neshev, Pepo ^d   Kahle, Gunther ^f  

^a European Pharmaceutical Clinical Sciences   (France)

^b Medical Affairs   (Switzerland)

^c Bausch and Lomb   (Germany)

^d Prywatny Gabinet Okulistyczny ^*  (Bulgaria)

^e Prywatny Gabinet Okulistyczny   (Poland)

^f Private Practice in Ophthalmology   (Germany)

Author keywords

Intraocular pressure; Latanoprost 0.005 ; Ocular hypertension; Primary open angle glaucoma; Prostaglandin analogs; Xalatan

Indexed keywords

EYE DROPS; LATANOPROST;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BIOEQUIVALENCE; BLURRED VISION; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; EYE DISCHARGE; EYE PAIN; FEMALE; FOLLOW UP; FOREIGN BODY SENSATION; HUMAN; INSTILLATION SITE BURNING; INSTILLATION SITE DISCOMFORT; INSTILLATION SITE ITCHING; INSTILLATION SITE STINGING; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE LOWERING EFFECT; KERATOCONJUNCTIVITIS SICCA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PARALLEL DESIGN; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VITAL SIGN;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; THERAPEUTIC EQUIVALENCY; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 81855196000     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000041     Document Type: Article

References (24)

1. Peeters A, Webers C, Prins MH, Zeegers M P, Hendrikse F, Schouten JS. Quantifying the effect of intraocular pressure reduction on the occurrence of glaucoma. Acta Ophthalmol 2010; 88: 5-11.
2. Baudouin C, Rouland J F, Nordmann J P, Bron A, Pelen F. Efficacy of first- or second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension. J Fr Ophtalmol 2006; 29: 615-24.
3. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Phar-macother 2002; 36: 504-11.
4. Sellem E, Rouland JF, Baudouin C, et al. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination. BMC Ophthalmol 2010; 10: 10.
5. Patel SS, Spencer CM, Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 1996; 9: 363-78.
6. Denis P, Baudouin C, Bron A, et al. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol 2010; 10: 4.
7. Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol 2010; 4: 741-64.
8. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 2008; 115: 790-5.
9. Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol 2008; 53(Suppl 1): 107-20.
10. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13; discussion 829-30.
11. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Oph-thalmol 2000; 130: 429-40.
12. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000; 10: 95-104.
13. O'Donoghue E P, Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomized study. Br J Ophthalmol 2000; 84: 579-82.
14. van der Valk R, Webers CA, Schouten JS, Zeegers M P, Hen-drikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112: 1177-85.
15. Lindén C, Alm A. Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes. Acta Ophthalmol Scand 1997; 75: 412-5.
16. Alm A, Widengård I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995; 79: 12-6.
17. Nagasubramanian S, Sheth G P, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology 1993; 100: 1305-11.
18. Lindén C, Alm A. Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Curr Eye Res 1998; 17: 567-72.
19. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006; 47: 2917-23.
20. Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology 2001; 108: 1439-44.
21. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 2003; 13(Suppl 4): S44-S52.
22. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140: 598-606.
23. Stewart WC, Kolker AE, Stewart JA, Leech J, Jackson AL. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003; 135: 314-20.
24. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004; 137(Suppl): S3-S12.